as 06-30-2025 4:00pm EST
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Founded: | 1987 | Country: | Ireland |
Employees: | N/A | City: | DUBLIN 4 |
Market Cap: | 5.1B | IPO Year: | 1991 |
Target Price: | $40.00 | AVG Volume (30 days): | 1.6M |
Analyst Decision: | Buy | Number of Analysts: | 12 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 2.09 | EPS Growth: | -17.49 |
52 Week Low/High: | $22.90 - $36.45 | Next Earning Date: | 07-23-2025 |
Revenue: | $1,513,770,000 | Revenue Growth: | -12.30% |
Revenue Growth (this year): | -9.35% | Revenue Growth (next year): | 4.25% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Nichols Christian Todd | ALKS | SVP, Chief Commercial Officer | Jun 9 '25 | Sell | $31.52 | 6,667 | $210,143.41 | 89,542 |
ALKS Breaking Stock News: Dive into ALKS Ticker-Specific Updates for Smart Investing
TipRanks
13 days ago
MT Newswires
14 days ago
MT Newswires
14 days ago
Zacks
a month ago
PR Newswire
a month ago
PR Newswire
a month ago
Simply Wall St.
a month ago
PR Newswire
a month ago
The information presented on this page, "ALKS Alkermes plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.